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Abstract: Background and Objective: Diabetes mellitus (DM) is a common long-term disease which 
can be related with salivary amylase levels. DM has recently been associated with salivary amylase 
diagnostics that could further impair diagnoses in the diabetic population, as well as being an inter-
esting alternative to traditional methods of determine glucose levels. The main advantage of this 
method is related to the fact that it is a fast diagnostic method. The DM population experiences 
changes to their metabolism which affects their salivary parameters, making this an alternative pro-
cedure for diagnosis and follow-up of the illness due to the non-invasive nature of salivary analyzes. 
The objective of this review is to summarize the evidence regarding the changes in salivary amylase 
and glucose levels, and their relationship with blood markers of glycemic control used in clinical 
settings such as blood glucose and glycated hemoglobin. The differences in salivary amylase levels 
depending on the method of saliva collection under fasting or non-fasting conditions. The changes 
in salivary amylase depends on the type of diabetes, the type of insulin treatment or the quality of 
glycemic control. Conclusions: Salivary amylase concentration is increased in diabetic patients in 
most of the studies and salivary glucose concentration in all studies in both fasting and non-fasting 
(post-prandial) conditions. Salivary amylase and glucose concentration represent potential non-in-
vasive biomarkers to evaluate glycemic control and clinical management of diabetic patients, alt-
hough it is necessary to evaluate the influence of potential modulating factors such as age, duration 
diseases, sex and the effects of pharmacological treatments in these outcomes which remained to be 
elucidated. 
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1. Introduction 
Diabetes mellitus (DM) is a metabolic disease with a high prevalence worldwide, so 
it is an important global public health problem. Estimates suggest that 425 million people 
will have diabetes by 2025, which represents about 10% of the world’s habitants, and 90% 
of the diabetic population suffer from type 2 diabetes [1]. The acute complications of dia-
betes and its chronic complications, such as nephropathy, retinopathy, cardio-vascular 
diseases or diabetic foot, have been associated with hospitalizations and may be a cause 
of mortality [2,3]. 
The gold standard for measuring glycemic levels has traditionally been blood analy-
sis of glucose and glycated hemoglobin by venous puncture and capillary venous punc-
ture at home and subsequent use of glucometers. However the collection and analysis of 
blood test require an invasive approach and time to obtain the results. Point-of-care test-
ing (POC), that is, the analysis of patients’ specimens outside the clinical laboratory, near 
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or at the site of patient care, and usually performed by clinical staff without laboratory 
training, has recently been proposed as a rapid tool which is accessible for the patient and 
can be acted upon immediately. The key factor is the concept that clinical decision making 
may be delayed when samples are sent to the clinical laboratory [4]. This preventive action 
may cause unnecessary anxiety, especially in young populations [5] and people with neu-
ropsychiatric disorders [6,7]. For these reasons, non-invasive procedures can be an alter-
native method for measuring glucose levels, which limits the possibility of stress-induced 
hyperglycemic states. 
Salivary markers are non-invasive diagnosis tools that can overcome these limita-
tions, and they can help clinical decisions at POC in diabetic patients as is the case with 
recently proposed salivary biomarkers in other pathologies. Salivary glucose is present in 
concentrations of 0.5 to 1 mg/dL, this increases mainly after the ingestion of food and bev-
erages, as well as depending on the concentration of glucose in the blood. Prior research 
has shown good correlations between salivary glucose (stimulated and unstimulated con-
ditions) levels using different techniques and glucose levels in blood [8]. Glycated proteins 
such as HbA1C can be compared with salivary markers, such as serum cortisol levels, 
salivary cortisol, plasma and prolactin levels [9], other putative diabetic markers [10], and 
the enzyme representing the first glycemic controlling enzyme in food digestion (i.e., sal-
ivary amylase) [11]. Moreover, fast blood glucose and salivary glucose test marks have 
been correlated significantly in patients with DM [12,13] and there is, in turn, a positive 
correlation between fast salivary glucose testing and HbA1c [12,14] and other salivary 
markers, for example, fructosamine glycated protein showed a significant correlation with 
HbA1c and blood glucose [15] 
However the predictive value of the salivary glucose test can be modified due to bac-
terial flora in the mouth [15], hydration and certain drugs [13]. For this reason, this diag-
nosis method should be considered carefully and other salivary biomarkers could be more 
valid alternatives than glucose determination in saliva [16]. Blood glucose levels after 
starch intake are influenced by genetically determined differences in salivary amylase, an 
enzyme that breaks down dietary starches. In particular, the activity of higher salivary 
amylase is related to lower levels of blood glucose [17]. In fact, individuals with high con-
centrations of salivary amylase had significantly lower postprandial blood glucose re-
sponses following starch ingestion compared to individuals with low amount of the en-
zyme, this difference being apparently mediated by the increased plasma insulin concen-
trations in those individuals with high levels of the enzyme [17]. Nevertheless, both 
groups had similar plasma glucose and insulin responses following glucose ingestion. 
Thus, it is unlikely that group differences were due to innate differences either in their 
ability to produce insulin or in their capacity for insulin-mediated glucose disposal. Inter-
estingly, the activity of salivary amylase has been associated with stress that increases it 
by stimulating the sympathetic autonomic nervous system, and as such it is considered a 
widely accepted marker of sympathetic activity in the body. Salivary amylase levels have 
been proposed as biological markers closely related to perceived stress in different phys-
iological and pathological situations [18–20]. The measurement of salivary amylase is; 
therefore, an interesting useful marker for evaluating glycemic control in different patho-
logical situations accompanied by an increase in the activation of the sympathetic system. 
In addition, which can; therefore, alter glycemic control and act as a marker of these stress-
mediated changes in patients with diabetes. 
The aim of this scoping review was to systemically evaluate the current evidence on 
employing salivary amylase and its associations with glycemic status in saliva in diabetic 
patients. A comparative analysis of salivary amylase concentration and activity was also 
performed for common blood glycemic parameters used in diabetes patients in clinical 
settings, such as blood glucose and HbA1c concentration. 
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2. Materials and Methods 
We analyzed all original articles available in the most widely used scientific data-
bases (e.g., in PubMed/Medline and Scopus), published until October 2020, with no date 
limitations and fulfilling the following inclusion criteria: (1) Full text in English, Spanish 
or Portuguese; (2) primary articles only; and (3) measurement of amylase levels in saliva; 
(4) diabetic patients. When determining the articles to include, we analyzed the title and 
abstract, and the full text for articles that fulfilled the inclusion criteria. Finally, the refer-
ence lists of all relevant articles were manually cross-referenced to identify additional ar-
ticles. The search terms employed were “diabetes” AND “saliv*” AND “glucose” OR 
“amylase”). 
Each article was evaluated by two independent reviewers, and any discrepancy was 
resolved by a third reviewer. Each reviewer evaluated the main characteristics of the stud-
ies described, indicating whether these fulfilled the eligibility criteria. 
Data Extraction 
As a consequence of the large number of references to studies found in the database 
search, an Excel® sheet was designed to facilitate the selection process, acting as a data 
collection form in which the codification of the items (criteria) to evaluate were clearly 
identified 
3. Results 
3.1. Summary of Identified Studies 
A total of 167 studies were found by searching in databases. After eliminating dupli-
cates, 32 were analyzed to prepare the scoping review (Figure 1). After reading the full 
texts, seven of the studies were not analyzed due to failing to meet the inclusion criteria; 
six of them analyzed blood amylase [21–26], one of them studied the differential clearance 
of isoamylases [27]. Five researchers independently summarized the results extracted 
from these articles. 
 
Figure 1. Preferred reporting items for systematic reviews and meta-analyzes (PRISMA) workflow 
for literature searches. 
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Table 1. Sociodemographic profile of subjects, type of diabetes mellitus (DM) and type of saliva and blood sampling. 
Author, Year n (Patients/Controls) Type of DM 
DM Patients (Mean ± SD; 
Median (Range)/% Men) 









al., 2017 [28] 
20/20 T2D 47.6 ± 8.6/50 46.6 ± 8.4/50 Fasting, between 7 and 8 a.m. Unstimulated Postprandrial 
Artino et al., 1998 
[29] 
17 ID, 14 NIDD/16 IDD and NIDD 39.7/47 ID, 56.4/50 DNID 43.8/50 
Fasting before breakfast from 7:30 
to 8:00 a.m.and fasting in the 
afternoon from 5:30 to 6:00 p.m. 
after at least 90 min of digestive 
rest 
Unstimulated NA 
Aydin et al., 2007 
[30] 
20 O, 20 NO/22 T2D 47/55 O, 48/50 NO 49/45.5 Fasting,at 8 a.m. before breakfast Unstimulated NA 
Ben-Aryeh et al., 
1988 [31] 
35/31 T2D 31.2 ± 7.4/57 29.0 ± 6.2/54.8 
Non-fasting 1 h after meal from 8 
to 11 a.m. 
Two samples, the 
first unstimulated 
and the second 
stimulated with 
citric acid 
At the same time as 
saliva sampling 





Total Range (55–75)/25% NA 
From 9 a.m. to 12 p.m., after 120 
min without oral stimulus 
Unstimulated NA 
Choukaife el al., 
2018 [33] 
45/30 NIDD 30.7 ± 5.6/66.6  28.3 ± 5.4/66.6 
Non-fasting 1 h after meal from 8 
to 11 a.m. 
Two samples, the 
first unstimulated 




Dodds et al., [34]  45/36 NIDD 50 ± 1.5/26.66 55.2 ± 1.7/36.11 Fasting (2 h) Unstimulated Fasting 





(HbA1C > 8% 
and 5 years at 
least of DM) 
35.6 ± 9.9/75%  34.7 ± 8.2/NA 




on paraffin wax 
NA 
Indira et al., 2013 
[36] 
20/20 T2D 50.38 ± 6.57/50% 




et al., 2019 [37] 
30 U, 30 C/30  T2D 
55.16 ± 2.2/33.3 U, 
50.76 ± 1.97/43.3 C  
49 ± 1.4/46.6 
Non-fasting 1 h after meal from 8 
to 11 a.m. 
Unstimulated NA 
Landgrota et al., 
2016 [38] 
60/60 T1D and T2D 52.32 ± 8.05/68.3 48.33 ± 7.30/53.3 
Non-fasting, 2 h after breakfast 




88/39 T1D and T2D 52 ± 18/64.8 23 ± 6/43.6 Non-fasting Unstimulated NA 
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López et al., 2003 
[40] 
20/21 T1D 9.4 ± 3.9/45 8.3± 1.8/42.9 Fasting Unstimulated NA 
Malathi et al., 2013 
[11] 
33/34 T2D NIDD 47.21 ± 7.82/50 46.44 ± 7.5/50 NA NA 
Fasting and 
postpandrial 
Newrick et al., [41] 8NP,8NNP/8 NA 
53 (32–78) NP/NA, 55 (35–
83)NNP/NA 
23 (18–30) 





Panchbhai et al., 
2010 [42] 
40 U, 40 C/40 T1D and T2D 
48.50 ± 7.86/45 U 
49.50 ± 10.88/37.5 C 
46.12 ± 10.25/40 
Non-fasting after 1 h meal from 8 
to 11 a.m. 
Two samples, the 
first unstimulated 




Prathibba et al., 
2013 [43]  
30/30 T2D 48.14 (53.3) 44.44/46.6 Fasting between 7 and 8:30 a.m. Unstimulated NA 
Piras et al., 2010 
[44] 
4 T1D, 5 T2D/11 T1D and T2D Total Range (42–68) - Biopsia of parotid gland - NA 
Reuterving et al., 
1987 [45] 
11/NA T1D and T2D 28.7/72.7 NA Fasting after 1 h meal before noon 
Stimulated by 
parafilm 
Fasting after 1 h eating 
Reznick et al., 2006 
[46] 
11 U, 9 C/12 NA 15.1/50 U, 15/45.5 C 16.5/44.4 
In the morning after 90 min 
without oral stimulus  
Unstimulated NA 
Sathyapriya et al., 
2016 [47] 
60/25 T1D and T2D 56.5 ± 14.3/50 46.6 ± 18.2/50 Fasting from 8 to 11 a.m. Unstimulated Fasting, at 8 to 11 a.m. 
Siddiqui et al., 2015 
[48] 
125/125 NIDD 46.91 ± 8.3/37.6 43.74 ± 7.54/34.4 Fasting at 8:00 a.m. Unstimulated 
Fasting and 
postpandrial 
Tenovuo et al., 1986 
[49] 
35/35 IDD 30.4 (17–61)/68.57 Age and sex matched 
Non-fasting after 1 h meal from 8 




Tiongco et al., 2019 
[10] 
25/55 NA NA NA NA Unstimulated NA 
Yavuzyilmaz et al., 
1996 [50] 17/17 IDD and NIDD 54.23 ± 15.82/58.8 23.17 ± 3.26/41.4 
Non-fasting after 1 h meal from 8 
to 11 a.m. Unstimulated NA 
NA: Not available, T1D: Type 1 diabetes, T2D: Type 2 diabetes, IDD: Insulin-dependent diabetes, NIDD: Non-insulin-dependent diabetes, O: Obese, NO: Non-obese 
and diabetic; U: Uncontrolled Diabetics, C: Controlled diabetics, A: Diabetics and albuminuria; MA: Diabetics and microalbuminuria. 
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3.2. Main Characteristics of the Studies’ Subjects 
Twenty-five of the included studies obtained the saliva sample directly from the oral 
fluid, and the remaining one [44] quantified the data by obtaining a biopsy specimen of 
the parotid gland. All the studies compared diabetic patients with healthy controls, except 
one longitudinal study [45] that analyzed a sample of diabetics at two points in time in 
different diabetic controls. In addition, several studies differentiated between controlled 
and uncontrolled diabetics within the diabetic group [37,42,46,47], or according to the 
presence of obesity [30] or according to the presence of neuropathy [41]. Table 1 shows 
the baseline characteristics of the 24 studies included. Most studies include adults with 
Type 2 diabetes (T2D) [11,28,30–32,36,37] or both types (T1D and T2D) [38,39,42,44,45,47], 
and in some studies, the participants were classified not according to the type of diabetes 
(i.e., type I or II), but instead based on their current insulin treatment (i.e., as non-insulin-
dependent diabetes (NIDD) [33,34,48,50], insulin-dependent diabetes (IDD) [49] or both 
[29]). Finally, López et al. [40] and Hirtz [35] included T1D in children. Only three studies 
did not specify the type of diabetes [10,41,46]. 
3.3. Saliva and Blood Sampling 
The saliva samples were obtained under fasted conditions in the morning before 
breakfast in seven studies [28–30,40,43,47,48] and from 1 to 2 h after a meal in thirteen 
studies [28–33,35–37,40,41,43,44]. In addition, most studies obtained the saliva sample 
without stimulation, while others obtained it after stimulation with paraffin [35,45,49] or 
citric acid [41]. Some studies also analyzed both unstimulated and stimulated individuals 
[31,33,42]. 
Some studies also collected blood samples under fasted conditions [34,38,47], and 
non-fasting/postprandial conditions [28,31,33,45] or both [11,48]. In addition, some of the 
samples were from veins [11,47] and from capillaries [28,34]. 
3.3.1. Salivary Flow Rate in DM 
The flow rate was analyzed in some studies, and only showed significant differences 
between the groups in unstimulated saliva samples in children with T1D [40], being lower 
in diabetic patients compared to the control group, although the increase falls within the 
normal range. On the other hand, in stimulated saliva samples, Ben-Aryeh et al. [31], 
Choukaife et al. [33] and Prathiba et al. [43] found significant differences in T2D, with 
lower rates in the diabetic groups. Newrik et al. [41] found the most significant differences 
between neuropathic individuals and controls (0.06 vs. 0.53 mL/min), but no differences 
were observed between non-neuropathic diabetic patients and non-diabetic individuals. 
3.3.2. Salivary Amylase Levels 
The concentration of salivary amylase has been determined mainly by two tech-
niques, that is, commercially available enzyme-linked immunosorbent assay (ELISA) 
based on a rapid immunochemical reaction test [28,37,39] and both amylase content and 
activity by biochemical assays based on colorimetric reactions employing chromogenic 
starch substrates [10,11,27–29,31,32,34,36–39,41,43–46]. Among enzymatic methods, the 
Phadebas® method [51,52] is particularly easy to perform, shows high accuracy and is 
commercially available. Phadebas is a synthetic biochemical substrate used for both qual-
itative and quantitative assessment of the α-amylase enzyme. Its active component is 
DSM-P (degradable starch microspheres), in which a blue dye has been chemically bound. 
When the substrate is digested by the amylase enzyme, it releases that blue dye at a rate 
proportional to the quantity of the enzyme present. Amylase content can also quantified 
by immunocytochemistry technique in parotid gland tissue [44]. Finally, two studies 
[32,35] applied label-free differential protein expression analysis using mass spectrome-
try. Some studies analyzed differences in salivary amylase concentration by sex and age, 
and none of them found any differences and correlations by age [28,37,39,40,42,48,49]. 
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In the unstimulated saliva samples, the amylase levels were statistically significantly 
higher in diabetic patients in ten studies [10,11,29,31,36–39,46] and also in the study by 
Piras et al. [44] performed in parotid gland tissue. The increase in amylase concentration 
was generally observed in both the fasting [28,30,40] and non-fasting samples [10,11,37–
39,47]. In contrast, four studies [36,41,42,49] reported significantly lower levels in diabetic 
patients than in controls; three of them under non-fasting conditions [36,42,50] and only 
one in a fasting sample [43]. Among the most recent techniques to analyze protein expres-
sion in biological samples, proteomics provides high accuracy and sensitivity of proteome 
analysis; the hybrid platforms of multidimensional separations and mass spectrometry 
have provided the most powerful solution. Multidimensional separations provide en-
hanced peak capacity and reduce sample complexity, which enables mass spectrometry 
to analyze more proteins with high sensitivity [53]. The changes in amylase concentration 
in saliva samples in diabetic patients have been demonstrated by using two-dimensional 
gel electrophoresis coupled with matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF/MS)[35] or multidimensional liquid chromatog-
raphy/tandem mass spectrometry (2D-LC-MS/MS) [32]. Another three studies found no 
differences between the groups [29,46,48] (Table 2). In stimulated and non-fasting sam-
ples, only the study by Dodds et al. [34] also obtained higher levels for diabetic patients 
compared to the control group (Table 3). 
3.3.3. Salivary Glucose Levels and Hb1ac Levels 
Salivary glucose levels were statistically higher in diabetic patients, ranging from 1.26 
to 11 mg/dL, than in controls, ranging from 0.5 to 4.8 mg/dL. Significant differences were 
also observed between blood glucose levels, which ranged from 173 to 327 mg/dL in dia-
betics and 83 to 122 mg/dL in healthy controls. Hb1Ac was also higher in diabetic patients 
(ranges 7.22% to 17.3%) than in healthy controls. Analysis of the results concerning sali-
vary glucose concentration showed that, in fasting conditions, there is a major increase in 
glucose concentration in the saliva of diabetic patients compared to its levels in blood 
samples. The magnitude of such an increase is two-fold in three studies [10,28,40] and in 
the majority of the studies the increase in salivary glucose concentration was by three-fold 
and more. The increase in salivary glucose is three times or more in diabetic patients than 
in controls, and it appears similar in fasting or in those studies in which salivary glucose 
concentration has been measured 1–2 h postprandial. 
3.3.4. Correlations between Salivary Amylase and Blood Glucose Levels 
Only five studies correlate salivary amylase with salivary glucose concentration. The 
study of Panchbai et al. [42] showed a significant correlation in the uncontrolled group, 
whereby salivary amylase was lower in diabetic patients (although with very small statis-
tical significance). On the other hand, in the study by Tiongco et al. [10], salivary amylase 
was higher in diabetics and they found a significant correlation between fasting blood 
glucose and salivary amylase (r = 0.226, p = 0.04) and also with salivary glucose (r = 0.416; 
p < 0.001). Three studies found no significant correlation [28,33,48] 
In addition, there were correlations between salivary amylase and blood glucose lev-
els in non-fasting samples, ranging from r = 0.138, p < 0.05 (43) to r = 0.226, p < 0.001 [10]. 
Indira et al.[36] and Kheirdman et al. [37] found no correlations. 
As regards other correlation parameters, salivary amylase correlates with salivary 
total protein (r = 0.4842, p < 0.05) in the studies by Indira et al. [36], Panchbai et al. [42] and 
Ben-Aryeh et al. [31]. Lima-Aragao et al. [39] constructed a ROC curve to validate the 
salivary parameters that could be used for diagnostic testing. A test was considered posi-
tive in the event of alterations in glucose, total protein, urea, IgA and amylase concentra-
tions. The sensitivity of the test was 88%, specificity was 90%, and the diagnostic accuracy 
was 89%. The salivary parameters of diabetic patients showed an AUC in salivary param-
eters of 0.99 for glucose, 0.98 for total protein, 0.95 for amylase, 0.84 for IgA, 0.81 for urea 
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and 0.55 for calcium (all parameters p < 0.0001). Tiongco et al. [10] also showed an AUC 
in salivary glucose of 0.811 p < 0.001 and of 0.649 p < 0.05 in salivary amylase. 
3.3.5. Enzymatic Activity of Salivary Amylase in Diabetics 
Artino et al. [29] measured salivary amylase activity (measured as the ratio to protein 
quantity and saliva volume to remove protein-related variations), which presented mini-
mum levels in the morning and maximum levels in the afternoon. There were no signifi-
cant differences between the groups. Reznick et al. [46] found no differences between the 
groups, but the amylase activity in the DM-uncontrolled group was substantial (by 122%, 
p = 0.07). Dodds et al. [34] attempted to determine whether alterations in glycemic control 
alter amylase activity. Paired saliva samples from subjects with blood glucose levels of at 
least 150 mg/dL who subsequently showed improved glycemic control (defined simply as 
a reduction in fasting blood glucose levels) were compared for amylase activity. A signif-
icant reduction in amylase activity and production (862 ± 94.3 before vs. 410.8 ± 76.5 after 
U/mL, p < 0.0001) occurred concomitantly with the fall in blood glucose levels. When the 
opposite situation was studied (i.e., patients showing increases in blood glucose (from 
levels ≥ 135 mg/dL to levels ≤ 170 mg/dL)), there was a non-significant increase in amylase 
activity (364 ± 51.7 before vs. 422 ± 74.3 after, U/mL p > 0.05). 
3.3.6. Correlation between Salivary Amylase and Diabetic Complications 
Only Kheirdman et al. [37] analyzed the differences of salivary amylase in the pres-
ence of oral pathologies. The levels of salivary amylase were higher in oral candidiasis 
and erythematous candidiasis, but no other correlations with salivary IgA and periodon-
tal disease were found. 
Two studies [31,33] analyzed the presence of diabetic complications as clinical char-
acteristics of sample. The prevalence of those complications was from 28.5% to 57.8% for 
skin problems, from 5.7% to 6.67% for nephropathy, from 24.4% to 25.7% for retinopathy, 
from 20% to 31.1% for neuropathy, and 8.5% for peripheral vascular disease. These studies 
did not analyze salivary amylase according to the prevalence of these complications. 
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Controls (Mean ± 












et al., 2017 [28] 
U/L 
2164.3 ± 578.2 vs. 885 ± 
434 *** 
Higher *** NA 
10.9 ± 10.11 vs. 4.8 ± 
0.62 *** 
PPBG 287 ± 34.65 
vs. 122.2 ± 9.34 
*** 
7.22 ± 1.25 vs. 
2.86 ± 0.56 *** 
NS NA 
NS differences by 
sex and age in 
both groups 




Morning: 25,000 IDD, 
175,000 NIDD vs. 
190,000 ¥ 
Afternoon: 51,000 IDD, 
390,000 NIDD vs. 
40,500 ¥ 
NS NA NA NA NA NA NA 
The increase in 
the salivary flow 
rate in the 
afternoon is 
accompanied by 
a decline in S-
total protein 
concentration 
Aydin et al., 
2007 [30] 
U/mL 
628 ± 62 O, 612 ± 57 NO 
vs. 494 ± 44 
O vs. Controls **, O vs. 
NO*, NO vs. Controls * 
Higher * 
0.97 ± 0.2 O, 
1.09 ± 0.1 NO 
vs. 1.2 ± 0.3 
3.9 ± 0.8 O, 3.8 ± 0.6 
NO vs. 1.3 ± 0.3 
O vs. C **, O vs. 
NO*, NO vs. C * 
NA NA NA NA 
No differences 
between groups 
in total protein 
Border et al., 
2012 [32] 











Indira et al., 
2013 [36] 
U/mL 
107.66 ± 28.60 vs. 154.96 
± 25.07 *** 
Lower *** NA 
8.4 ± 4.59 vs. 1.65 ± 
0.30 *** 
282.25 ± 42.81vs 
109.55 ± 11.19 *** 
NA 
r = −0.3328, 
NS 
r = −0.3098, NS 
Significant 
differences were 









amylase (r = 
0.4842)* and S-
glucose (r = 
−0.5181)* 
Kheirmand 
Parizi et al., 
2019 [37] 
U/L 
161,852 U vs. 95,793 C 
vs. 63,295 
*** U vs. controls 
** U vs. C 
Higher *** NA NA NA 
r = −0.172 U, r = 
−0.166 C 
r = −0.096 
Controls, NS 
NA 
r = −0.293 U, r = 
−0.222 C 
r = 0.096 Controls, NS 
No correlation in 
S-amylase 
content by sex 
and age in both 
groups 
 
Lodgrota et al., 
2016 [38] 
 
1671.42 ± 569.86 
vs1397.59 ± 415.97 
Higher ** NA 
14.10 ± 6.99 vs. 5.87 
± 2.42 *** 
211.50 ± 43.82 
88.81 ± 11.29 *** 
NA NA NA - 
Lima-Aragão, 
2016 [39] 





López et al., 
2003 [40] 
AU/dL 
58.8 ± 37.4 vs. 35.5 ± 
16.8 ** 
Higher ** 
0.2 ± 0.1 vs. 0.3 
± 0.1 *** 







NA NA NA 
NS differences in 









were lower than 
the levels in 
adults.  
Malathi et al., 
2013 [11] 
U/L 
2739.48 ± 1525.2 vs. 
1740.38 ± 638.51 *** 
Higher *** NA NA 
173.88 ± 72.02 vs. 
83.21 ± 9.84 ** 
PP 247.88 ± 86.37 
vs. 141.62 ± 
154.08 * 
7.79 ± 1.15 vs. 
5.15 ± 0.60 *** 
NA NA 






poor oral hygiene 









mild to moderate 
gingivitis. 
Panchbhai et 
al., 2010 [42] U/mL 
108.48 ± 6.37 U vs. 
100.83 ± 60.77 C vs. 
146.72 ± 10.70 
* C vs. Controls 
Lower* 
Unst: 
0.18 ± 0.12 U vs. 
0.18 ± 0.14 C vs. 
0.21 ± 0.20 
St: 
0.51 ± 0.27 U vs. 
0.48 ± 0.29 C vs. 
0.57 ± 0.35 
8.09 ± 6.45 U vs. 7.65 
± 6.44 C vs. 1.89 
±1.44 




glucose * and 
S-total 
protein *** in 
U 
With S-total 
protein ** in 
C 
 
No differences in 
S-amylase by sex 
between groups 
Prathibba et al., 
2013 [43]  
 
19.20 ± 1.8 vs. 92.51 ± 
13.74 
Lower ** 
0.46 ± 0.02 vs. 
0.67 ± 0.04 ** 
17.31 ± 2.05 vs. 4.33 
± 0.29 *** 
NA NA NA NA - 
Piras et al., año 
[44] 
NA 
10.27 ± 0.67 T1D vs. 2.83 
± 0.41 T2D vs. 3.27 ± 
0.63 
** T1D vs. Controls 
Higher ** NA NA NA NA NA NA - 
Reznick et al., 
2006 [46] 
IU/L 
988 (187–2596) U vs. 
333 (18–3670) C vs. 466 
(4–1968) 
NS 
P = 0.078 U 
vs. Controls 
NA NA NA NA NA NA - 
Sathyapriya et 
al., 2016 [47] 
U/mL 
G2 (<100 mg/dL) 102.32 
± 67.61, G3 (100–150 
mg/dL) 106.83 ± 60.77, 
G4 (150–250 
mg/dL)108.48 ± 6.37, 
G5 (>250 mg/dL) 111.12 
± 11.94/96.72 ± 10.70* 
Higher * NA 
G2 (<100 mg/dL) 
7.30 ± 5.84, G3 (100–
150 mg/dL) 7.64 ± 
6.44, G4 (150–250 
mg/dL) 8.09 ± 6.45, 
G5 (>250 mg/dL) 
9.04 ± 7.17/5.91 ± 
2.19 * 
NA NA NA NA 
A correlation was 
found between S-
amylase and S-
total protein  
Siddiqui et al., 
2015 [48] 
nKat/L 
1.48 ± 1.15 vs. 1.24 ± 
0.71 
NS NA NA NA NA NS 
with PPBG (r = 0.138) 
* 
No correlation in 
S-amylase by sex 
 
Tiongco et al., 
2019 [10] 
U/L 
930.8 ± 827.0 vs. 613.5 ± 
667.3 * 
Higher * NA 
12.6 ± 10.5 vs. 5.4 ± 
8.7 ** 
174.5 ± 92.7 vs. 
94.1 ± 17.4 ** 
S-glucose (r = 
0.416) *** and 
FBG (r = 0.226) ** 
NA  
AUC for DM 
diagnoses en S-





71.7 ±21.7 vs. 92.2 
± 97.2, NS 




al., 1996 [50] 
U/mL 
124.2 ± 79.7 vs. 228.2 ± 
185.5 * 
Lower * NA NA 165 ± 51 vs. NA NA NA NA 
IDD 112.25 ± 
76.37 
NIDD 130.7 ± 82.2 
¥ Estimated from graphic, NA: Not available, NS: Not significant, Significant at * p < 0.05 ** p < 0.001 *** p < 0.0001, S-amylase: Salivary amylase. S-glucose: Salivary glucose; S-total 
protein: Salivary total protein; S-ghrelin: Salivary ghrelin NA: Not available, PP: Post-prandial, PPBG: Postprandial blood glucose, FBG: Fasting blood glucose, T1D: Type 1 diabetes, T2D: 
Type 2 diabetes, IDD: Insulin-dependent diabetes, NIDD Non-insulin-dependent diabetes, O: Obese and diabetic, NO: Non obese and diabetic; U: Uncontrolled diabetics, C: Controlled 
diabetics, AUC: Area under the curve, G2: Blood sugar level < 100 mg/dL; G3: Blood sugar level 100–150 mg/dL, G4: Blood sugar level 150–250 mg/dL, G5: Blood sugar level > 250 
mg/dL. 
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Flow rate (Mean ± 




vs. Controls  




Diabetics vs. Controls 

















al., 1988 [31] 
102 IU/£ 
WR: 6026 ± 3753 vs. 
6325 ± 4003 
RP: 11,287 ± 3159 vs. 
11,861 ± 4592 
SP: 9930 ± 4089 vs. 
11,200 ± 3140 
NS 
0.35 ± 0.24 vs. 0.48 ± 
0.23 *  
WR: 2.9 ± 5.8 vs. 1.5 ± 
1.0  
RP:3.2 ± 2.7 vs. 0.7 ± 
0.6 *** 
SP: 1.9 ± 1.6 vs. 0.3 ± 
0.3 *** 
236 ± 66 vs. 80 ± 10 *** NA NA NA 





S-amylase and total 





WR: 5022 ± 2417 vs. 
7590 ± 3652 
RP:10,064 ± 4227 vs. 
113,425 ± 66,457  
SP:8697 ± 4125 vs. 
12,465 ± 5920 
NS 
0,29 ± 0,17 vs. 0,58 ± 
0,26 * 
WR 3.48 ± 6.11 vs. 
1.28 ± 0.88 
RP 3.82 ± 2.90 vs. 0.58 
± 0.26 ***  
SP 
2.27 ± 1.82 vs. 0.25 ± 
0.1 *** 
283 ± 71 vs. 68 ± 6.62 ** NA NS NA 
No differences 




found in WS and 
SP and differences 
in k were found in 
RPS, SP and WS 
Hirtz et al., 
2006[35] 
Spots NA Lower * NA NA NA NA NA NA 
The spots were 
detected in nearly 
all subjects and 




Dodds et al., 
[34] 
U/ml 
537.0 ± 36.3 vs. 431.2 ± 
30.08 * 
Higher * 
WR 0.41 ± 0.04 vs. 
0.45 ± 0.05 
SP 0.34 ± 0.03 vs. 0.35 
± 0.03 
NA 
198.6 ± 10.3 vs. 97.3 ± 
3.3 *** 
NA NA NA 
Amylase activity 
before/after in the 
same group: 
SRBG 862 ± 94.3 
vs410.8 ± 76.5 *** 
SIBG 364 ± 51.7 vs. 
422 ± 74.3, NS 







vs. 488 (123–2443) NP 
vs. 727 (242–1400)  
NS 
0.55 (0.31–0.8) NNP, 
0.15 (0.06–0.36) NP 
vs. 0.68 (0.53–0.85) ** 
NP vs. Controls 
NA 
261.32 (180–360) NNP 
vs. 216 (144–252) NP 
NA Controls 
12 (7–19) NNP 
vs. 12 (9–14) 
NP 
NA NA - 
Reuterving et 
al., 1987 [45] 
 
U/ml 
One group, two 
moments: 0.33 ± 0.04 
Fst vs. 0.55 ± 0.18 Snd 
- 
WR:0.05 ± 0.02 vs. 
0.09 ± 0.02  
RP:0.04 ± 0.012 vs. 
0.07 ± 0.03 
SP:0.62 ± 0.11 vs. 0.57 
± 0.07 
WR:4.32 ± 0.72 vs. 
1.26 ± 0.18 * 
RP:4.14 ± 1.26 vs. 1.62 
± 0.36 * 
SP:1.26 ± 0.36 vs. 0.36 
± 0.18 ** 
327.35± 158.54 vs. 
105.21 ± 48.46 
11.5 ± 1.86 vs. 
7.92 ± 1.78 ** 
NA NA 





al., 1986 [49] 
U/mL3 233 ± 154 vs. 277 ± 136 NS 
1.47 0.63 vs. 1.62 ± 
0.74 
NA NA  NA  
No correlation for 
S-amylase by age. 
Diabetics have 
more Iga, IgG and 
peroxidase activity 
in saliva than 
controls 
S-amylase: Salivary amylase. S-glucose: Salivary glucose WR: Whole resting; RP: Resting parotid; SP: Stimulated parotid; S-IgA: Salivary IgA ¥ Estimated from graphic, Significant at * 
p < 0.05 ** p < 0.001 *** p < 0.0001, NA: Not available, PPBG: Post prandial blood glucose, T1D: Type 1 diabetes, T2D: Type 2 diabetes, IDD: insulin-dependent diabetes, NIDD Non-
insulin-dependent diabetes, NDD: New diagnosed diabetes, O: Obese, NO: Non-obese and diabetic; U: Uncontrolled diabetics, C: Controlled diabetics, A: Diabetics and albuminuria; 
MA: Diabetics and microalbuminuria, AUC: Area under the curve. Fst: First moment worse control, Snd: Second better control; SRBG: Subjects with reduced blood glucose, SIBG: 
Subjects with increased blood glucose. 
 




There has been increasing interest in salivary biomarkers in recent years. The main 
justification for their use is their ability to monitor how and when a disease starts and how 
it progresses, and to observe the outcome of treatment in promoting health and well-be-
ing. To that end, there must be specific biomarkers associated with the state of health or 
disease, which can be detected and monitored in a non-invasive way, and technologies 
that discriminate these biomarkers are required [54]. Salivary biomarkers meet the second 
requirement and, after analyzing research studies, the first and third are fulfilled. Salivary 
amylase plays an important role in the oral cavity. Both complex carbohydrates and sim-
ple carbohydrates changes into glucose [30]. Diabetes, due to its association with the au-
tonomic system, modifies the quantity of saliva, the composition of amylase levels and 
other salivary biomarkers [43] related to catecholamine, and other substances such as cor-
tisol. This scoping review endeavors to analyze the role of salivary amylase as a potential 
biomarker for diabetes mellitus, comparing the concentration of salivary amylase in dia-
betics (T1D, T2D, IDD and NID) with healthy controls or after an intervention to improve 
diabetic control. Although the first studies were published more than three decades ago, 
research on this subject has increased in the last ten years. 
Salivary amylase starts the hydrolysis of starch in the mouth, and this process ac-
counts for no more than 30% of the total hydrolysis of starch. Because salivary amylase is 
inactivated by an acidic pH, no significant hydrolysis of carbohydrates occurs in the stom-
ach [55]. The acinar cells, which produce salivary amylase, are also innervated by sympa-
thetic and parasympathetic pathways. Activation of the sympathetic nervous system in-
creases amylase synthesis, which increases the concentration of amylase in saliva, and 
parasympathetic activity increases the saliva flow rate with little or no effect on amylase 
synthesis. Salivary amylase is related to the autonomic system and it is involved in in 
glycemic digestion, so it could be a good biomarker for assessment and follow-up DM, 
[56]. 
The heterogeneity of the studies analyzed in terms of type of diabetic population, 
together with the different ways results are presented by the authors, from how the saliva 
sample is collected to how the salivary amylase is expressed and what they really want to 
measure (concentration, secretion or activity), means that comparison of the results is dif-
ficult [57]. 
Most studies show higher levels of salivary amylase in DM patients in unstimulated 
samples. Diabetic patients have altered expression of amylase and cyclic adenosine mono-
phosphate (cAMP) receptors in the parotid gland, and this could lead to changes in the 
production of salivary proteins, and particularly for salivary amylase [56]. In addition, 
there is an increase in the permeability of the basal membrane, which could allow a leak-
age of proteins in saliva through the salivary glands [10,38,43,58]. Only one study shows 
the same results in stimulated samples, and the others found no differences, which could 
be due to the mechanical stimulation of the saliva secretion changing the protein content 
of the saliva due to different content of the parotid and submandibular glands. Salivary 
flow is controlled by the autonomic nervous system, and mainly by the parasympathetic 
nervous system. The parasympathetic innervation of the parotid gland is caused by the 
glossopharyngeal nerve (cranial pair IX), via the optic ganglion. The facial nerve (cranial 
nerve VII) provides the parasympathetic innervation to the submandibular and sublin-
gual glands, via the submandibular ganglion [54]. In passive sampling, only 20% of saliva 
will come from the parotid glands, which have more salivary amylase than the submaxil-
lary and sublingual glands [59]. If they are stimulated, no differences in concentration are 
obtained and changes of between 25% to 40% can occur [57]. Other aspects that should be 
emphasized regarding the collection of saliva samples are that, in healthy people, salivary 
amylase has a particular diurnal profile, declining immediately after awakening and in-
creasing constantly during the morning and afternoon [29,56]. Therefore, the collection of 
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saliva samples should take place according to the same schedule (about 1 h after awaken-
ing) and the collection range should not be too long [31,42,49,60]. Lastly, the saliva collec-
tion method also interferes with the data obtained from salivary amylase. The use of cot-
ton sponges could lead to salivary amylase measurement errors, with nearly complete 
salivary amylase retention when the cotton absorbs 0.25 mL of saliva. This means that the 
amount of saliva, which is related to the flow rate and/or duration of collection, will indi-
rectly influence the salivary amylase levels. The drooling method or spitting method 
should; therefore, be used as a first step if there is no alteration of salivary flow, and ab-
sorbent products are required under conditions such as strenuous exercise or with pa-
tients with alterations in saliva secretion, such as xerostomia [57]. 
The differences in salivary amylase levels depending on the method of saliva collec-
tion under fasting conditions are uncertain, since differences with higher levels were ob-
served under both fasting [28,30,40,60] and non-fasting conditions [11,37,39,46,61]. The 
heterogeneity of the results depending on the type of diabetes, the type of insulin treat-
ment or control of the disease may also depend on whether the sample is collected under 
fasting or non-fasting conditions [62]. Conducting studies with uniform criteria would 
enable results to be unified for comparison. 
Meanwhile, six studies [32,35,36,42,43,50] showed lower levels in diabetic patients 
than healthy controls. The authors attribute these levels to hormonal and metabolic 
changes in diabetic patients, such as microvascular complications and autonomic neurop-
athy, both of which may affect salivary secretions [41]. Hirtz [35], which uses mass spec-
trometry analysis, speculated whether the under-accumulation of α-amylase spots in di-
abetic patients could be related to changes in oral anti-inflammatory status. In addition, 
they also suggest that the diabetes would affect selectively only a part of α-amylase 
isoforms. 
These apparent discrepancies could also be due to the saliva collection method, and 
other factors that could be involved in salivary amylase levels, such as years of evolution 
of DM [63], neurological comorbidity [56] such as Parkinson’s disease [64], and other pa-
thologies that alter salivary flow such as gastro-esophageal reflux [65]. Other possible fac-
tors include the use of drugs that act on the parasympathetic system, such as pilocarpine, 
myorelaxants, anti-epileptic and anti-psychotic drugs; treatment that interferes with the 
action of acetylcholine, such as anticholinergics, antihistamines and cytostatic; and head 
and neck radiation therapy [54]. Therefore, all these aspects should be taken into account 
in the recruitment of subjects or as confounding factors in the analysis of data. 
All the studies found higher levels of salivary glucose and blood glucose in diabetic 
patients, since this is a diagnostic criteria, but few studies analyzed their correlation with 
salivary amylase. When interpreting these results, the limitations on obtaining salivary 
amylase mentioned above could explain their variability. A positive correlation with 
blood parameters was observed for unstimulated and non-fasting samples [37,42,48]. Sal-
ivary amylase and blood glucose are positively correlated in studies with similar saliva 
sample collection characteristics. Salivary amylase also shows a good correlation for total 
salivary proteins [36,47] and with blood amylase [61]. It should be noted that, in these 
analyses, not all parameters present a good correlation between saliva and blood accord-
ing to the studies above, in addition to variations in concentration depending on saliva 
flow in the case of polar or ionic compounds of high molecular weight transported by 
saliva or secreted by exocytosis [54]. 
Two studies reported correlations with several metabolites which could be used in 
the clinical setting as a diagnostic value in DM, and obtained the highest value for the area 
under the curve for salivary glucose, followed by salivary amylase [39,61]. 
Several authors analyzed enzymatic activity, but found no conclusive results, alt-
hough its activity is increased in uncontrolled patients [46] and reduced in those who con-
trol their glucose levels [34]. More studies are necessary to better understand these as-
pects, since salivary amylase could play an important role in the follow-up of diabetic 
patients 
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Few studies analyzed the salivary amylase levels in the presence of DM complica-
tions. Salivary amylase secretion is directly related to the autonomic system, and the par-
asympathetic denervation of the parotid gland in diabetic neuropathy may follow a gen-
eralized distribution in autonomic neuropathy [41]. Two studies analyzed the prevalence 
of complications, but both obtained stimulated samples showing salivary amylase levels 
which were lower but not significant [33,66]. Only one showed increased salivary amylase 
in the presence of oral candidiasis [37], where saliva plays an important role in its immune 
function in both the control of bacteria and virus adherence [67]. 
Replacing blood tests with other samples such as saliva in order to perform a non-
invasive process is becoming increasingly postulated for several pathologies, and it is par-
ticularly useful for those patients with neurocognitive disorders or children in which 
blood sampling, for instance, is very stressful. This is primarily because it is cheaper than 
determining blood levels, and it is a non-invasive procedure, and easy to store. It is also 
less infectious than blood, is easier to handle in diagnostic procedures and does not clot 
[54]. 
Although it is not possible to make clear recommendations about the use of salivary 
amylase measurements in diabetic patients for diagnostic purposes, the results of the 
scoping review suggest important technical and clinical issues for future studies in this 
research field. The recruitment of subjects should take into account the presence of comor-
bidities, years of suffering from DM and distinguish between T1D, T2DID and T2DNID. 
The possible drugs involved in obtaining saliva samples should also be assessed. The col-
lection method should be unstimulated after 1 h awake and use a split or dropping 
method, if there are no problems such as xerostomia. The presence of complications re-
lated to the evolution of DM (neuropathy, nephropathy, retinopathy, dermatological al-
terations) must be considered in order to assess the prognostic levels of salivary amylase 
for DM assessment and to evaluate the effects of interventions aimed to improve glycemic 
status. 
5. Conclusions 
Salivary amylase content is increased in diabetic patients compared to non-diabetic 
individuals in most of the studies analyzed in this review. The increase in salivary amylase 
concentration was generally observed in samples collected in fasting and non-fasting 
(measured 1 to 2 h from meal intake) conditions. The majority of the studies reported an 
increase in salivary glucose concentration in individuals with diabetes by three-fold and 
more, suggesting similar biochemical alterations at the basis of the increase in these two 
biomarkers of glycemic index in saliva. The increase in salivary glucose appears consistent 
and replicated in saliva samples collected both after fasting and non-fasting conditions. 
However, a direct correlation analysis between the two salivary biomarkers (amylase and 
glucose) has been seldom investigated and the results are conflicting. No clear conclusions 
can be done regarding the association between salivary amylase changes in diabetes pa-
tients and glycemic control in blood and the presence of diabetic complications. Future 
studies are clearly necessary to address these issues for diagnostic purposes of putative 
salivary biomarkers. 
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